How Much Does Evenity (Romosozumab) Cost in Nevada in 2026?

Evenity List Price and Cash-Pay Cost in Nevada

The manufacturer list price for Evenity is $1,825 per monthly dose in 2026, and Nevada retail pharmacies reflect this same figure for cash-pay patients [1]. A full treatment course spans 12 consecutive monthly injections, placing the total cash-pay cost near $21,900 before any discounts or insurance adjustments.

Each monthly dose consists of two prefilled syringes, each containing 105 mg of romosozumab, administered subcutaneously. The drug is typically given in a physician's office or infusion center, though self-administration at home is permitted per the FDA-approved labeling [2]. Specialty pharmacies in Las Vegas and Reno tend to price at list or within 2% of it. Buy-and-bill arrangements through orthopedic or endocrinology practices may yield slightly different out-of-pocket figures depending on the practice's acquisition cost, but discounts below list price are uncommon for cash-pay patients without manufacturer support. Patients paying entirely out of pocket should request a predetermination letter from the prescribing practice to confirm the exact per-dose charge before beginning the 12-month course.

Nevada Medicaid Coverage for Evenity

Nevada Medicaid does not cover Evenity as of mid-2026 [1]. This exclusion applies to both fee-for-service Medicaid and Nevada's managed care organizations, including Anthem Blue Cross Blue Shield of Nevada, Molina Healthcare, and Health Plan of Nevada when administering Medicaid benefits.

The gap is significant. Romosozumab is the only anabolic bone-building agent with a sclerostin-inhibition mechanism, and its exclusion from the Nevada Medicaid formulary leaves a subset of high-risk osteoporosis patients without access to the most effective fracture-reduction therapy available. In the ARCH trial (N=4,093), romosozumab followed by alendronate reduced new vertebral fracture incidence by 48% compared with alendronate alone over 24 months [3]. For Medicaid beneficiaries in Nevada who meet clinical criteria, the practical options are limited: appeal the denial through the Medicaid fair hearing process, apply to the Amgen Safety Net Foundation for free drug access, or discuss alternative anabolic agents like teriparatide (Forteo) or abaloparatide (Tymlos), which may have different formulary status. Physicians filing appeals should document prior fracture history, bone mineral density T-scores, and failure or intolerance of first-line bisphosphonates.

Private Insurance and Medicare Coverage in Nevada

Most major commercial insurers in Nevada cover Evenity with prior authorization. The typical approval criteria mirror the 2020 AACE/ACE Clinical Practice Guidelines for postmenopausal osteoporosis: a DXA T-score of -2.5 or below at the spine or hip, or a history of fragility fracture, combined with documented trial of or contraindication to at least one oral bisphosphonate [4]. UnitedHealthcare, Aetna, and Cigna plans sold in Nevada generally classify Evenity as a specialty tier drug with step-therapy requirements.

Medicare Part B covers Evenity under the medical benefit when administered in a provider's office, which is the most common setting. The standard Part B cost-sharing is 20% after the annual deductible, meaning a patient without supplemental coverage would owe approximately $365 per injection, or $4,380 across the full course. Medicare Advantage plans in Nevada (Humana, AARP/UnitedHealthcare, and Alignment Healthcare are the largest by enrollment) may apply different prior authorization timelines, but coverage rates are comparable. Patients enrolled in a Medicare Supplement (Medigap) plan with Part B excess coverage can reduce out-of-pocket costs to near zero.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown and past president of the National Osteoporosis Foundation, has noted: "For patients with very high fracture risk, starting with an anabolic agent like romosozumab and then transitioning to an antiresorptive gives you the best long-term fracture reduction. The sequencing matters as much as the drug itself" [5].

The Amgen / UCB Savings Card and Patient Assistance

Amgen and UCB jointly offer two financial assistance programs that Nevada residents can access. The first is the Evenity copay savings card, available to commercially insured patients. Eligible patients pay as little as $0 per dose, with the program covering up to a specified annual maximum (currently around $15,000 per year for most enrollees). The card cannot be used with Medicare, Medicaid, or other federal or state government insurance.

The second program is the Amgen Safety Net Foundation, a separate patient assistance program for uninsured or underinsured patients. Qualifying income thresholds are typically set at 400% of the federal poverty level or below. Approved applicants receive Evenity at no cost for the full 12-dose course. Application processing takes 5 to 10 business days, and the prescribing provider's office usually handles enrollment. Nevada patients who fall into the coverage gap (not Medicaid-eligible but unable to afford commercial premiums with adequate specialty drug coverage) should apply to Safety Net before beginning treatment.

One often-missed detail: the savings card requires re-enrollment each calendar year. Patients starting treatment in September or later may need to re-enroll partway through their 12-dose course.

Can You Get Compounded Romosozumab in Nevada?

No, not in any practical sense. Romosozumab is a humanized monoclonal antibody, a complex biologic produced through recombinant DNA technology in Chinese hamster ovary (CHO) cells [2]. While Nevada does license 503A compounding pharmacies, the molecular complexity of monoclonal antibodies makes them impossible to replicate through traditional compounding methods. A 503A pharmacy can compound small-molecule drugs from bulk ingredients, but it cannot manufacture a 149-kDa glycoprotein with the required post-translational modifications.

The FDA's position is clear. Biologics like romosozumab fall under the Public Health Service Act (Section 351), not the Federal Food, Drug, and Cosmetic Act (Section 503A), which governs traditional compounding [6]. Any pharmacy claiming to offer "compounded romosozumab" in Nevada would be operating outside federal law. Patients should treat such claims with skepticism. The only legitimate lower-cost pathway remains manufacturer patient assistance or insurance coverage optimization.

Telehealth Prescribing of Evenity in Nevada

Nevada permits telehealth prescribing of Evenity. The Nevada State Board of Medical Examiners allows physicians licensed in Nevada to prescribe specialty medications, including injectable biologics, through synchronous telemedicine encounters [7]. This is particularly relevant for patients in rural Nevada counties (Elko, Nye, Humboldt, White Pine) where access to endocrinologists or rheumatologists with osteoporosis expertise may require a 200+ mile drive to Reno or Las Vegas.

A telehealth consultation can handle the prescribing and prior authorization steps. The patient still needs a local facility for DXA scanning and may need an in-person visit for the first injection if they are not comfortable with self-administration. Several national osteoporosis telehealth platforms now serve Nevada, and HealthRX offers telehealth consultations for patients exploring bone-health treatment options.

Clinical Evidence Behind Romosozumab

Romosozumab received FDA approval in April 2019 based primarily on two large phase III trials. The FRAME trial (N=7,180) compared romosozumab to placebo in postmenopausal women with osteoporosis. At 12 months, romosozumab reduced the risk of new vertebral fractures by 73% (0.5% vs. 1.8%, P<0.001) [5]. After transitioning to denosumab for the second year, the fracture-reduction benefit persisted.

The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior fragility fracture. Over 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% and clinical fractures by 27% compared with alendronate alone [3]. Hip fracture reduction reached 38%. These results positioned romosozumab as the most effective initial therapy for patients at very high fracture risk.

The 2020 AACE/ACE guidelines formally recommend romosozumab as a first-line option for patients at "very high" fracture risk, defined as a recent fracture (within 24 months), fractures while on approved osteoporosis therapy, multiple fractures, T-score below -3.0, or high FRAX probability [4].

One safety signal requires discussion. The ARCH trial found a numerical imbalance in adjudicated serious cardiovascular events: 50 in the romosozumab group versus 38 in the alendronate group during the first 12 months [3]. The FDA labeling carries a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year [2]. The Endocrine Society's 2019 guideline update states: "Romosozumab should not be initiated in patients with recent cardiovascular events, but the absolute cardiovascular risk in the broader osteoporosis population remains low and should be weighed against fracture risk" [8].

Who Qualifies for Romosozumab Treatment

The FDA-approved indication is for postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other osteoporosis therapies [2]. In clinical practice, prescribers in Nevada also use romosozumab off-label for men with osteoporosis and for glucocorticoid-induced osteoporosis, though insurance coverage for these indications may require additional documentation.

Before prescribing, the treating physician should verify three things: no history of myocardial infarction or stroke within the prior 12 months, adequate calcium and vitamin D levels (correcting deficiency before starting treatment), and the patient's ability to adhere to a monthly injection schedule for 12 consecutive months. Post-romosozumab sequencing is not optional. Bone density gains reverse rapidly if an antiresorptive (typically denosumab or a bisphosphonate) is not started immediately after the 12th dose [5].

Comparing Romosozumab Costs to Other Osteoporosis Drugs in Nevada

Cost context matters. Generic alendronate (the most commonly prescribed osteoporosis drug) runs $10 to $30 per month at Nevada pharmacies. Denosumab (Prolia) lists at approximately $1,950 per six-month injection, or about $325 per month. Teriparatide (Forteo) costs roughly $3,600 per month at list price, though the generic version (available since 2023) has brought cash-pay prices closer to $1,200 to $1,800 per month at Nevada specialty pharmacies. Abaloparatide (Tymlos) lists at approximately $2,500 per month.

Romosozumab at $1,825 per month is less expensive per month than brand teriparatide and abaloparatide, and its treatment duration is shorter: 12 months versus 24 months for teriparatide and abaloparatide. The total cost of a romosozumab course ($21,900) is lower than a full teriparatide course at list price ($86,400 over 24 months) [9]. Cost-effectiveness analyses published in the Journal of Bone and Mineral Research have found romosozumab-to-alendronate sequencing to be cost-effective at a willingness-to-pay threshold of $150,000 per quality-adjusted life-year in patients at very high fracture risk [10].

Nevada patients weighing these options should discuss the clinical rationale for anabolic-first therapy with their prescriber. The strongest evidence supports romosozumab as initial therapy specifically for patients with recent fractures or T-scores below -3.0, where the speed of bone density gains during the first 12 months can prevent the next fracture during the highest-risk window [3][4].